High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients
Authors:
- Ercument DiriceEDErcument Dirice
- Ozlem ElpekOEOzlem Elpek
- Aylin Fidan KorcumAKAylin Fidan Korcum
- Mustafa OzdoganMOMustafa Ozdogan
- Inci SuleymanlarISInci Suleymanlar
- Mustafa Kemal BalciMBMustafa Kemal Balci
- Thomas S. GriffithTGThomas S. Griffith
- Salih SanliogluSSSalih Sanlioglu
- 1 March 2009
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 38 (2) , 154-160
Abstract
The importance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in pancreatic carcinoma development is not known. To reveal the putative connection of TRAIL and TRAIL receptor expression profile to this process, we analyzed and compared the expression profile of TRAIL and its receptors in pancreatic tissues of both noncancer patients and patients with pancreatic ductal adenocarcinoma (PDAC). Thirty-one noncancer patients and 34 PDAC patients were included in the study. TRAIL and TRAIL receptor expression profiles were determined by immunohistochemistry. Annexin V binding revealed the apoptotic index in pancreas. Lastly, the tumor grade, tumor stage, tumor diameter, perineural invasion, and number of lymph node metastasis were used for comparison purposes. TRAIL decoy receptor 2 (DcR2) and death receptor 4 expression were up-regulated in PDAC patients compared with noncancer patients, and the ductal cells of PDAC patients displayed significant levels of apoptosis. In addition, acinar cells from PDAC patients had higher DcR2 expression but lower death receptor 4 expression. Increased DcR2 expression was also observed in Langerhans islets of PDAC patients. Differential alteration of TRAIL and TRAIL receptor expression profiles in PDAC patients suggest that the TRAIL/TRAIL receptor system may play a pivotal role during pancreatic carcinoma development.Keywords
This publication has 38 references indexed in Scilit:
- Molecular mechanisms of death ligand‐mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetesJournal of Cellular Biochemistry, 2008
- Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritisRheumatology, 2007
- Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cellsMolecular Cancer Therapeutics, 2006
- TRAIL promotes metastasis of human pancreatic ductal adenocarcinomaOncogene, 2006
- Adenovirus-mediated IKKβKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosisCancer Gene Therapy, 2005
- Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoterCancer Gene Therapy, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cellsOncogene, 2001
- Pancreatic adenocarcinomaCurrent Problems in Cancer, 1996
- Pancreatic CarcinomaNew England Journal of Medicine, 1992